Jianjun Chen

42PUBLICATIONS
23CO-AUTHORS
Molecular targetsInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Industrial molecular engineering of nucleic acids and proteinsOrganometallic chemistry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Mar 08, 2026
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy.

Zichao Yang, Ziqing Liu, Jiayi Zhou

|Feb 17, 2026
Exogenous Epstein-Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy.

Changlin Liu, Zhiqiang Sun, Chao Li

|Dec 04, 2025
Targeted NAT10 Degradation by PROTAC NP1192 Suppresses Hypoxia-Adaptive Glycolysis and Reinvigorates CD8<sup>+</sup> Effector T‑Cell Function for Synergistic Cancer Immunotherapy.

Keyi Ao, Zhiqiang Sun, Yi Hao

|Aug 15, 2025
Discovery of Rigid Linker-Based IRAK4 PROTACs with Improved Metabolic Stability for the Treatment of Inflammatory Diseases.

Yapeng Fan, Rongxiang Ma, Kabonde Makasa Njobvu

|Jul 18, 2025
Base-Catalyzed Aqueous Methylenation of Imidazo[1,2-<i>a</i>]pyridines with Glyoxylic Acid: Synthesis of Bis(imidazo[1,2-<i>a</i>]pyridin-3-yl)methanes.

Yinrong Wu, Xixiang Yang, Lin Yuan

|Jul 15, 2025
Correction to "Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities".

Shuqing Li, Wanyi Pan, Chengpeng Tao

Pageof 7

Frequent Collaborators

4 joint publications

Shuwen Liu

4 joint publications

Xiaopeng Peng

3 joint publications

Yingfeng Tu

3 joint publications

Binbin Cheng